PUBLIC NOTICE OF ABC SALE: Mythic Therapeutics Inc

SALE OF INTELLECTUAL PROPERTY – Mythic Therapeutics Inc.

Mythic Therapeutics Inc. (“Mythic” or “Assignor”) executed a General Assignment for the Benefit of Creditors in favor of Mythic ABC, LLC (the “Assignee”). The Assignee is now soliciting offers for the sale of Mythic’s intellectual property and brand-related assets including, but not limited to:

• FateControl TM
  o Clinically proven to enhance ADC payload delivery to tumor cells while reducing uptake
  in healthy cells.
  o Works through engineered pH-dependent ADC release in the endolysosome,
  overcoming key barriers like target degradation and ADC recycling.
  o Payload agnostic technology supporting MYTX-011 and two additional development
  candidates (DCs) ready for IND-enabling studies (≈19 months to IND).
  o Broad platform protected by 7 patent families spanning solid and hematologic cancers.
• MYTX-011
  o Clinically validated cMET-targeted DAR2-MMAE ADC with >230 treated NSCLC patients
  showing strong safety and >30% ORR in cMET-positive tumors across squamous, non-
  squamous, EGFR-mutant, and wild-type disease.
  o Significant commercial potential with at least two ~$2B opportunities: 2L cMET-positive
  squamous NSCLC and 2L cMET-low NSCLC.
• LRRC15
  o Targets cancer-associated fibroblasts (CAFs) in breast, NSCLC, and various sarcomas.
  o Optimized for CAF-specific delivery, showing enhanced antitumor activity in five
  xenograft models.
  o Exhibits Q2W–Q3W dosing potential and a well-tolerated PK profile in cynomolgus
  monkeys.
• PTK7
  o ADC development candidate shows significantly greater efficacy than all clinical-stage
  PTK7 ADCs.
  o ADC antibodies tested across 4 xenograft models of breast, ovarian, SCLC, and NSCLC
  while maintaining similar pharmacokinetics and a clean tolerability profile in
  cynomolgus monkeys.
• Pipeline Families
  o Preliminary applications of FateControl TM to a wide range of additional targets across
  multiple solid tumor and hematological cancer indications

Mythic Background
Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, Massachusetts. The company’s mission is to develop next-generation antibody-drug conjugates (ADCs) using its proprietary “FateControl™” platform, which is designed to increase therapeutic payload uptake in cancer cells and reduce off-target toxicity. Mythic seeks to unlock the broader potential of ADCs by focusing on engineering the antibody component to control where and how the drug is delivered inside the cell and apply this to ADCs across payload classes.

Sale Process and Bid Deadline
The Assignee is marketing the assets for sale in whole, or in part. All interested parties must execute a confidentiality agreement prior to receiving access to the data room and further diligence materials.

Please direct all inquiries exclusively to the following professionals:

Development Specialists, Inc. (DSI)
Matthew P. Sorenson
Senior Managing Director
Phone: (213) 617-2717
Email: [email protected]

Development Specialists, Inc. (DSI)
Jack O’Brien
Associate
Phone: (872) 264-7138
Email: [email protected]

About DSI Assignments:
DSI Assignments specializes in providing experienced assignees to help businesses navigate financial distress. Operating within state laws, our team ensures transparent communication with creditors, manages stakeholder expectations, and negotiates with lenders and investors toward the maximal outcome. Led by Steven L. Victor and Matthew P. Sorenson, recognized experts in restructuring, bankruptcy, and assignments for the benefit of creditors (ABCs), DSI tailors each engagement to the unique needs of the business. ABCs offer an efficient alternative to bankruptcy, and our professionals are dedicated to maximizing value and creditor recoveries for stakeholders, including secured lenders, private equity and venture capital firms, principal of the distressed business, and boards of directors.